HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Olanow, C. W. Search for Related Content PubMed PubMed Citation Articles by Olanow, C. W.

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology.

The role of dopamine agonists in the treatment of early Parkinson’s disease

From the Department of Neurology, Mount Sinai School of Medicine, New York, NY.

Address correspondence and reprint requests to Dr. C. Warren Olanow, Department of Neurology, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, Annenberg 1494, Box 1137, New York, NY 10029.

Levodopa is the gold standard for the symptomatic treatment of Parkinson’s disease (PD). However, chronic treatment is associated with development of motor complications in the majority of patients. Recent laboratory studies suggest that pulsatile administration of a short-acting agent, such as levodopa, contributes to the development of these problems and that they might be mitigated through the use of longer-acting dopamine agonists. Placebo-controlled clinical trials have shown that dopamine agonists have anti-parkinsonian effects in patients with early PD. More importantly, four different prospective double-blind studies have demonstrated that initiating symptomatic therapy with a dopamine agonist is associated with a significantly reduced risk for development of motor complications than is initial treatment with a dopamine agonist. Furthermore, several lines of laboratory research suggest that dopamine agonists might protect dopaminergic neurons in PD and retard the rate of disease progression. Double-blind trials using clinical and imaging end points are now testing this hypothesis and the results should soon be available. On the basis of this evidence, a rational approach to the treatment of PD patients who are not elderly or cognitively impaired is to initiate therapy with a dopamine agonist and supplement with levodopa when dopamine agonist monotherapy can no longer provide satisfactory clinical control.

This article has been cited by other articles:

				P. Jenner Avoidance of dyskinesia: Preclinical evidence for continuous dopaminergic stimulation Neurology, January 13, 2004; 62(90011): S47 - 55. [Abstract] [Full Text]

				F. Stocchi and C. W. Olanow Continuous dopaminergic stimulation in early and advanced Parkinson's disease Neurology, January 13, 2004; 62(90011): S56 - 63. [Abstract] [Full Text]

				A.H. V. Schapira Disease-modifying strategies and challenges in PD: Interactive breakout sessions Neurology, September 23, 2003; 61(90063): S56 - 63. [Full Text]

				M. K. Loder and H. E. Melikian The Dopamine Transporter Constitutively Internalizes and Recycles in a Protein Kinase C-regulated Manner in Stably Transfected PC12 Cell Lines J. Biol. Chem., June 6, 2003; 278(24): 22168 - 22174. [Abstract] [Full Text] [PDF]